Glibclay 3 Tablet contains Glimepiride 3mg, a potent sulfonylurea used to improve glycemic control in patients with type-2 diabetes mellitus. It is effective in stimulating pancreatic insulin secretion and maintaining blood sugar levels within target ranges.
Glimepiride works by enhancing endogenous insulin release in response to elevated blood glucose, helping regulate both fasting and postprandial blood sugar levels. Its oral administration and once-daily dosing support patient adherence in long-term therapy.
This medicine is ideal for patients inadequately controlled on diet and exercise alone, offering reliable efficacy and a favorable safety profile. Its clinical use spans outpatient and hospital-based diabetes management programs.
Adding Glibclay 3 Tablet to your diabetes and metabolic-care portfolio strengthens your product offerings, creating strong opportunities in retail pharmacies, hospital supply, institutional distribution, export markets, and third-party manufacturing. Its high prescription rate ensures consistent demand and commercial viability.